128940.KS
128940.KS
KR7128940004
HanmiPharm
Loading chart...

Company Profile

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.

Related stocks

000100.KS
000100.KS • South Korea
Yuhan
73,100 KRW
4.08B USD 1Y -39%
4506.T
4506.T • Japan
SUMITOMO PHARMA CO LTD
1,591.5 JPY
4.51B USD 1Y -15.7%
GLAND.NS
GLAND.NS • India
GLAND PHARMA LIMITED
3,061.8 INR
5.22B USD 1Y +57.3%
600329.SS
600329.SS • China
TIANJIN PHARMACEUTICAL DA REN T
35.8 CNY
4.13B USD 1Y -17.6%
RGC
RGC • Hong Kong SAR China
Regencell Bioscience Holdings L
7.35 USD
3.64B USD 1Y -60.7%
300142.SZ
300142.SZ • China
WALVAX
14.75 CNY
3.53B USD 1Y +26%
600079.SS
600079.SS • China
HUMANWELL HEALTHCARE (GROUP) CO
19.23 CNY
4.7B USD 1Y -10.1%
000661.SZ
000661.SZ • China
CCHN
71.9 CNY
4.39B USD 1Y -44.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
49.2% p.a.
Max Drawdown (5Y)
-50.2%
Sharpe Ratio (5Y)
0.24
Beta Factor
0.53
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Elevated Short-Term Volatility: 3Y volatility (55.9%) is noticeably higher than the 5Y average (49.2%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (49.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -63.8% in the extended horizon.
ende